Usa was Ascendis Pharma A’s largest region in fiscal 2025, bringing in $546.39M of $733.03M (75%).
| Geography | FY 2015 | FY 2016 | FY 2017 | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Usa | — | $191.68M | $233.12M | $546.39M | |||||||
| Europe | $552.00K | $869.00K | $123.34M | $120.95M | |||||||
| Rest Of World | $6.47M | $74.17M | $7.19M | $52.80M | |||||||
| Denmark | — | — | — | $12.90M | |||||||
| North America | $44.16M | — | — | — | |||||||
| China | — | — | — | — | |||||||
| Asia | — | — | — | — | |||||||
| Germany | — | — | — | — | |||||||
| Switzerland | — | — | — | — | |||||||
| Total | $51.17M | $266.72M | $363.64M | $733.03M |
Ascendis Pharma A brought in $733.03M from its four regions in fiscal 2025, the year ended December 31, 2025. Ascendis Pharma A regrouped these regions after fiscal 2024, so the total does not compare directly with that year's $363.64M. Usa was the largest at $546.39M (74.5%), ahead of Europe at $120.95M (16.5%) and Rest Of World at $52.80M (7.2%). The remaining region, Denmark, brought in $12.90M.
Compared with fiscal 2024, Rest Of World grew fastest, up 634.3% to $52.80M, while Europe fell the most, down 1.9% to $120.95M.
Ascendis Pharma A began breaking out Denmark in fiscal 2025, when it brought in $12.90M. Ascendis Pharma A stopped reporting North America as a separate region after fiscal 2022, when it brought in $44.16M.
Commercial Customers was Ascendis Pharma A’s largest revenue line in fiscal 2022, bringing in $35.66M of $51.17M (70%).
| Major customers [axis] | FY 2016 | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2022 |
|---|---|---|---|---|---|---|
| Commercial Customers | — | — | $943.00K | $35.66M | ||
| Collaboration Partners & License Agreements | $13.38M | $6.95M | $6.84M | $15.52M | ||
| Visen Pharmaceuticals | — | — | — | — | ||
| Customer One | — | — | — | — | ||
| Other Collaboration Partners | — | — | — | — | ||
| Total | $13.38M | $6.95M | $7.78M | $51.17M |
Ascendis Pharma A brought in $51.17M from its two revenue lines in fiscal 2022, the year ended December 31, 2022. That was up 557.9% from $7.78M in fiscal 2021. Commercial Customers was the largest at $35.66M (69.7%), ahead of Collaboration Partners & License Agreements at $15.52M (30.3%).
Compared with fiscal 2021, Commercial Customers grew 3,681.4% to $35.66M and Collaboration Partners & License Agreements grew 127.0% to $15.52M.
Ascendis Pharma A began breaking out Commercial Customers in fiscal 2021, when it brought in $943.00K.
Goods Or Services Transferred At Point In Time was Ascendis Pharma A’s largest revenue line in fiscal 2022, bringing in $46.74M of $51.17M (91%).
| Timing of transfer of goods or services [axis] | FY 2019 | FY 2020 | FY 2021 | FY 2022 |
|---|---|---|---|---|
| Goods Or Services Transferred At Point In Time | $3.46M | $4.81M | $7.03M | $46.74M |
| Goods Or Services Transferred Over Time | $9.92M | $2.14M | $751.00K | $4.43M |
| Total | $13.38M | $6.95M | $7.78M | $51.17M |
Ascendis Pharma A brought in $51.17M from its two revenue lines in fiscal 2022, the year ended December 31, 2022. That was up 557.9% from $7.78M in fiscal 2021. Goods Or Services Transferred At Point In Time was the largest at $46.74M (91.3%), ahead of Goods Or Services Transferred Over Time at $4.43M (8.7%).
Compared with fiscal 2021, Goods Or Services Transferred At Point In Time grew 565.1% to $46.74M and Goods Or Services Transferred Over Time grew 490.4% to $4.43M. From fiscal 2019 to 2022, combined revenue from these revenue lines grew from $13.38M to $51.17M, a compound annual growth rate of 56.4%. Goods Or Services Transferred At Point In Time's share of the total rose from 25.8% to 91.3%.
Ascendis Pharma A (ASND) reports its revenue by geography, by major customers [axis] and by timing of transfer of goods or services [axis]. In fiscal 2025, Usa was its largest region, bringing in $546.39M (74.5% of the total), followed by Europe at $120.95M (16.5%).
Usa was Ascendis Pharma A's largest region in fiscal 2025, bringing in $546.39M, or 74.5% of the $733.03M total across its four regions.
Commercial Customers was Ascendis Pharma A's largest revenue line in fiscal 2022, bringing in $35.66M, or 69.7% of the $51.17M total across its two revenue lines.
Commercial Customers grew faster than Collaboration Partners & License Agreements in fiscal 2022, up 3,681.4% from $943.00K to $35.66M. Collaboration Partners & License Agreements grew 127.0% to $15.52M.
Every figure comes from Ascendis Pharma A's annual financial filings, as reported. Each line keeps the name Ascendis Pharma A gives it, and years follow its fiscal calendar.
Ascendis Pharma A's revenue by geography goes back to fiscal 2015, with figures through fiscal 2025. The latest four fiscal years are free to view, and the full history is available with a Business Quant subscription.